FDA FOCUS: The need for open clinical trial data for FDA approval

In the second of a monthly FDA-focused blog published exclusively by The Pharma Letter, Dr Nicola Davies looks at whether transparent clinical trials could impact FDA approval.

There is a strong international trend, in both the medical community and the public, demanding transparency from the pharmaceutical industry in drug testing and approval procedures. Large organizations, like the World Health Organization and the US National Institute of Health, along with the US Congress, the European Commission, and many other organizations, have joined the call for sharing the results of clinical trials; some are even calling for all raw data to be made public.